Methods: We assembled a retrospective analysis of patients (pts) diagnosed with LAEC and treated with preoperative chemoradiotherapy followed by esophagectomy (CRTþS), preceded or not by IC, between 2009 and 2017. Patients' characteristics, tumor variables and treatment outcomes were evaluated. Kaplan-Meier method was used to estimate overall survival and Cox proportional hazard model to evaluate prognostic factors. Results: 103 pts were studied, with a median age of 62 years (range 37-84). Seventy-five pts (73%) were male, 67 (65%) had squamous cell carcinoma and 31 (30%) adenocarcinoma. Forty-three pts (41,7%) received IC followed by CRTþS (ICþCRTþS). The most frequent IC consisted of paclitaxel and platinum (38 pts -90%) and the median number of cycles was 2 (range 1-6). All pts received CRTþS. Concurrent chemotherapy was a combination of paclitaxel and platinum in 94 pts (91%). The median radiation dose was 41.4 Gy (range 39.6-50.4). There was no statistically significant difference in pCR between the IC group and the standard CRTþS group. The pCR was 41.9% and 46.7% in the ICþCRTþS and CRTþS group (p ¼ 0,628), respectively. In the multivariate analysis, pCR was an independent prognostic factor for failure free survival (FFS) (HR 0.35, 95% CI 0.14-0.85, p ¼ 0.021), but not for overall survival (OS) (p ¼ 0.863). The factor that significantly affected OS in the multivariate analysis was positive lymph node (HR 5.9, 95% CI 1.23-28.27, p ¼ 0.026). IC, histology, histologic grade, radiation dose, T stage were not identified as independent prognostic factors for neither OS nor FFS.
Background: Neoadjuvant chemoradiation (nCRT) followed by surgery is the preferred treatment for locally advanced ESCC. But a recent trial suggested close observation might be a reasonable option in patients achieving clinical complete response (CR) to nCRT. For this strategy, accurate clinical assessment for predicting pathologic CR (pCR) is essential. In NCCN guidelines PET/CT is recommend as response assessment, whereas endoscopy is optional after nCRT. Methods: In 234 patients who received nCRT (46-50.4Gy) plus surgery for locally advanced ESCC at Asan Medical Center from 2007 to 2014, the performance of endoscopy and PET/CT which were done 4-8 weeks after nCRT for predicting pCR was evaluated. Metabolic CR (mCR) was defined as complete resolution of FDG uptake within all lesions, making them indistinguishable from surrounding tissue, and endoscopic CR (eCR) as no residual mucosal lesions except for scar change. Results: pCR (ypT0N0) was achieved in 108 patients (46.2%), and ypT0Nþ in 17 (7.3%). Among patients who underwent PET/CT (n ¼ 231), mCR was obtained in 102 (44.2%), and non-mCR in 81 (35.1%), whereas metabolic response could not be assessed due to diffuse esophagitis in 48 (20.8%). The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of mCR for pCR was 56.6%, 46.4%, 58.8%, and 71.6%, respectively. Among patients who underwent endoscopy (n ¼ 229), eCR was obtained in 42 (18.3%) , and the sensitivity, specificity, PPV, and NPV of eCR for pCR only in primary tumor site (ypT0Nþ/-) was 29.5%, 94.4%, 85.7%, and 54.0%, respectively. When adding endoscopic response to metabolic response, the sensitivity, specificity, PPV, and NPV of clinical CR for pCR was 27.9%, 94.3%, 80.6%, and 60.5%, respectively, and the positive likelihood ratio for pCR was 4.9 (95% CI 2.2-10.6).
Conclusions: The addition of endoscopic evaluation to metabolic response after nCRT improved specificity and PPV for pCR compared to metabolic response alone, which could help in applying surveillance strategy without immediate surgery in patients achieving clinical CR after nCRT for ESCC. Legal entity responsible for the study: Asan Medical Center. Funding: Asan Medical Center. Disclosure: All authors have declared no conflicts of interest.
634P Prognostic impact of inflammation-based scores in esophageal cancer
patients achieving pathologic complete response after neoadjuvant chemoradiotherapy followed by surgery Background: Despite several recent studies the association of sarcopenia with outcomes in oesophageal adenocarcinoma (OAC); in particular overall survival and dose limiting toxicity (DLT), remains unclear likely due to the heterogeneity of the populations included. There is therefore a need for studies of sarcopenia utilising large homogenously treated cohorts. Methods: We retrospectively collected data on DLT from 197 OAC patients treated with neoadjuvant chemotherapy at a single institution between August 2009 and September 2016. CT scans were visualised using the Worldmatch software package skeletal muscle at the L3 level was manually segmented. Published sex-specific cut-offs for skeletal muscle index (SMI) were used to classify patients as sarcopenic. Patients were further classified as sarcopenically obese if they had both sarcopenia and a BMI 30. Statistical analysis was completed using RStudio, Kaplan-Meier curves were plotted and differences in survival between sarcopenic and non-sarcopenic patients was analysed using a cox proportional hazards model. The Chi-squared test was used to analyse differences in toxicity between groups. Results: Sarcopenia was observed in 81% of patients. There was no correlation with age and SMI (r ¼ -0.1). Average SMI was greater in men than women (44.2 cm 2 /m 2 versus 33.7 cm 2 /m 2 , male versus female). Sarcopenic patients had a worse overall survival than non-sarcopenic patients (median OS, 28.0 months versus 19.3 months, p ¼ 0.0225). In contrast patients with sarcopenic obesity showed no difference in OS, in keeping with previous data. There was no significant difference between rates of DLT in patients with sarcopenia and those without (16.4% and 13.2% respectively, p > 0.05). There was a non-significant trend towards increasing rates of completion of 6 cycles of perioperative chemotherapy in non-sarcopenic patients (47% Vs 37% Also, significant differences in OS (P ¼ 0.004) were presented in failure pattern (LN vs. LF, P ¼ 0.004) and re-RT (RT vs. non-RT, P < 0.001). In terms of toxicities, there were 9.09% and 3.03% of tracheoesophageal fistulas, 15.15% and 3.03% of pericardial/pleural effusion in the RT and non-RT group, respectively (P > 0.05). The RT group had a higher rate of radiation pneumonitis (24.24% vs. 6.06%, P ¼ 0.039), but no pneumonia related deaths occurred.
Conclusions: Re-irradiation might improve the long-term prognosis of locoregional recurrent ESCC with a radiation history. Though the radiation pneumonitis is more frequent, re-irradiation is well tolerated. Legal entity responsible for the study: Junxin Wu. Background: A key aim of neoadjuvant therapy in oes cancer is to increase the chance of complete R0 resection. Microscopic residual disease after surgery is reported in around 30% cases, mainly involving the circumferential resection margin (CRM), with current staging techniques unable to accurately identify pts at risk of residual tumour at the CRM. Previous small single site studies have shown that high res T2-weighted MRI achieves detailed imaging of oes anatomy and has the potential to serve as an additional non-invasive staging modality. Methods: As part of the UK STO3 trial pts from participating centres with operable lower oes and type I/II OGJ adenoca were enrolled in the MRI observational sub-study. All pts underwent standard staging investigations, with additional MRI scans pre and post neoadjuvant chemo, followed by surgery. MRI parameters were consistent across sites and included CRM, T/N staging and apparent diffusion coefficient (ADC) assessment. Scans were reviewed locally and centrally to assess interobserver variability. Chemo response and association with pathological outcome were recorded. Results: Between Aug 2011 and Mar 2015 57 pts were recruited from 11 sites. Of these 32 had matched pre and post chemo scans and 28 had corresponding pathological outcome data available. Negative CRM status was correctly identified on post chemo MRI in 17/19 (89%) cases; positive CRM in 3/9 (33%) cases. When compared to pathological staging there was concordance between MRI T staging in 36% cases, with overstaging in 43% and understaging in 21%. Concordance between MRI and CT for T/N staging was 66% and 77% respectively. Tumour size reductions and ADC increases were observed during chemo. Local sites predicted significantly more CRM involvement than central review (48 vs 19%) . Conclusions: This represents the first prospective, multi-centre, national trial of MRI in oes cancer and is the first report of interobserver variability between treatment centres. Although limited by small numbers, MRI showed promising specificity to identify negative surgical margins and reasonable correlation with pathological outcome. Discrepancy between local and central review was observed, suggesting that more standardised methods of MRI assessment in oes cancer are required. Background: The aim of this study was to explore the prognostic value of diffusionweighted magnetic resonance imaging (DWI) 3D texture features in esophageal squamous cell carcinoma (ESCC) patients undergoing concurrent chemo-radiotherapy (CRT). Methods: We prospectively enrolled 82 cases with ESCC into a cohort study which underwent DWI before CRT. All MR examinations included axial T2WI, T1WI and diffusion-weighted sequences (b ¼ 0, b ¼ 600 s/mm 2 ). Two groups of tumor features were examined: (1) clinical features (eg, TNM stage, age and gender) and demographics; (2) spatial texture features of apparent diffusion coefficient (ADC), which characterize tumor intensity range, spatial patterns and distribution and associated changes resulting from CRT. A reproducible and no redundant feature set was statistically filtered and validated. The prognostic value of each parameter for overall survival was investigated using Kaplan-Meier and Cox regression models for univariate and multivariate analyses, respectively. Results: Both univariate and multivariate Cox model analyses showed that the radiation dose; IHIST_energy, m_contrast_1, m_clustershade_2, Diff_ClusetrTendency_2, Diff_homogeneity_2, m_lnversevariance_2, high intensity small zone emphasis (HISE) and low intensity large zone emphasis (LILE) associated significantly with survival. Our study showed seven 3D texture parameters extracted from ADC maps could distinguish high, median and low risk groups (Log-rank c 2 ¼9.7, P ¼ 0.00773). Conclusions: The ADC 3D texture features can be useful biomarkers to predict the survival of ESCC patients who received CRT. The combination of DWI texture and conventional prognostic factors can be used to generate robust predictive models for survival rate. Legal entity responsible for the study: Shandong Cancer Hospital. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
639P Volume reduction rate of the primary tumor of esophageal squamous cell carcinoma after neoadjuvant chemotherapy: Could this measurement be a surrogate end point for survival before surgery?
S. Nagasawa Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan, 2 Surgery, Yokohama City University, Yokohama, Japan, 3 Gastric Surgery Division, National Cancer Center Hospital, Tokyo, Japan Background: Neoadjuvant chemotherapy (NAC) followed by surgery is regarded as a standard treatment for Stage II and III resectable thoracic esophageal squamous cell carcinoma (ESCC) in Japan. In general, therapeutic effect of NAC against the primary tumor is estimated microscopically with resected specimen after surgery. Then, this microscopic assessment is validated as surrogating survival. However, as this assessment needs resected specimen, therapeutic effect could not be evaluated before surgery. The aim of this study was to investigate whether therapeutic effects in imaging findings obtained by calculating tumor volume reduction could be a surrogating survival or not. Methods: This retrospective study examined the patients who fulfilled the following criteria; (1) thoracic ESCC, (2) underwent esophagectomy following NAC between
